← Human Trials & Peer-Reviewed Studies
Effects of pramlintide, an amylin analogue, on gastric emptying in type 1 and 2 diabetes mellitus
Plain-language guide to PMID 11975712 (2002): placebo-controlled randomized controlled trial study of Amylin (Islet Amyloid Polypeptide) in 2 subjects.
Key Facts
- PMID
- 11975712
- Journal
- Neurogastroenterology and motility
- Year
- 2002
- Study type
- Randomized Controlled Trial
- Authors
- Vella A et al. (8 authors)
- DOI
- 10.1046/j.1365-2982.2002.00311.x
What This Study Did, in Plain Language
What Was Tested
Researchers studied Amylin (Islet Amyloid Polypeptide) in this randomized controlled trial publication.
Their aim was to determine whether the effects of pramlintide on gastric emptying differ in people with type 1 or type 2 diabetes who had no history of complications.
Why It Was Studied
Pramlintide delays gastric emptying, possibly by a centrally mediated mechanism.
Plasma pancreatic polypeptide (HPP) response to the test meal was also measured.
Who Took Part
The abstract describes 2 subjects taking part.
PubMed indexes the participants as middle-aged adults and older adults, both men and women.
How the Study Was Run
The researchers set it up as a randomized, placebo-controlled and crossover study.
Random assignment meant chance, not the researchers, decided who got Amylin (Islet Amyloid Polypeptide) and who got the comparison, which limits bias.
Some subjects received a placebo instead of Amylin (Islet Amyloid Polypeptide), giving a reference point.
Each person switched between Amylin (Islet Amyloid Polypeptide) and the comparison at some point, usually with a gap in between.
Gastric emptying of solids was measured by 13C-Spirulina breath test.
What Was Measured
Plasma pancreatic polypeptide (HPP) response to the test meal was also measured.
The subject headings attached to it are Amyloid, Anti-Ulcer Agents, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2, Gastric Emptying, Hypoglycemic Agents and Islet Amyloid Polypeptide.
What This Means in Plain Language
The paper is a randomized, placebo-controlled and crossover study of Amylin (Islet Amyloid Polypeptide) in 2 subjects.
With fewer than 40 people, it is a small study, so it is better read as an early signal for further research than as a settled answer.
The publication is from 2002 (Neurogastroenterology and motility), a journal based in England.
More context: the Amylin (Islet Amyloid Polypeptide) compound page, all human trials.
Our Notes on the Compound
Amylin (Islet Amyloid Polypeptide): A 37-amino-acid hormone released with insulin that slows stomach emptying and signals fullness; pramlintide (Symlin) is a synthetic version.
Related Pages
Source: PubMed record. This explanation is written by PeptideWhiz from the public record. For research and education only. Not medical advice; no dosing information is given.